Effect of atorvastatin on the lipid profile, markers of immune inflammation and symptomatic severity of heart failure in patients with myocarditis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Abstract. The effect of atorvastatin on the immune system and lipid metabolism after 24-week treatment of patients with chronic myocarditis is considered. Statins have been found to improve the clinical course of heart failure with a preserved ejection fraction in patients with myocarditis: they reduce the functional class of heart failure, improve the systolic function of the heart and its arrhythmogenic potential. Despite the large amount of conflicting data in the field of statin use in heart failure, one can think about the possible influence of molecular differences in statins on their pharmacological and pleiotropic effects. In particular, atorvastatin, which has lipophilic properties, is able to penetrate cardiomyocytes in contrast to hydrophilic rosuvastatin, which may partially explain the positive cardiac effects of atorvastatin in patients with heart failure with a preserved ejection fraction. The probable basis for the positive effect of atorvastatin on morphofunctional parameters in heart failure is its positive pleiotropic effects associated with a decrease in рro-inflammatory immune markers and subsequent leveling of negative neurohumoral activation. An additional mechanism that caused the positive effect of atorvastatin on the clinical course of heart failure can be considered a factor of preservation of systolic function of the left ventricle.

About the authors

N. N. Ryzhman

Military medical academy of S.M. Kirov

Author for correspondence.
Email: vmeda-nio@mil.ru
Russian Federation, Saint Petersburg

S. L. Grishaev

Military medical academy of S.M. Kirov

Email: vmeda-nio@mil.ru
Russian Federation, Saint Petersburg

D. V. Cherkashin

Military medical academy of S.M. Kirov

Email: vmeda-nio@mil.ru
Russian Federation, Saint Petersburg

E. V. Gladysheva

Military medical academy of S.M. Kirov

Email: vmeda-nio@mil.ru
Russian Federation, Saint Petersburg

V. Yu. Filippov

Military medical academy of S.M. Kirov

Email: vmeda-nio@mil.ru
Russian Federation, Saint Petersburg

G. G. Kutelev

Military medical academy of S.M. Kirov

Email: vmeda-nio@mil.ru
Russian Federation, Saint Petersburg

References

  1. Аронов, Д.М. Плейотропные эффекты статинов / Д.М. Аронов // Кардиология. – 2008. – № 8 (48). – С. 60–68.
  2. Гришаев, С.Л. Влияние терапии аторвастатином на клиническое течение хронической сердечной недостаточности неишемического генеза / С.Л. Гришаев [и др.] // Вестн. СПбГУ. – Сер. 11. Медицина. – 2016. – Вып. 4. – C. 15–25.
  3. Лишманов, Ю.Б. Радионуклидная диагностика для практических врачей: практическое руководство / Ю.Б. Лишманов, В.И. Чернов. – Томск: STT, 2004. – 394 с.
  4. Олейников, В.Э. Влияние аторвастатина на важнейшие механизмы аритмогенеза у больных инфарктом миокарда с подъемом сегмента ST / В.Э. Олейников [и др.] // Росс. кардиол. журн. – 2019. – № 7 (24). – С. 83–90.
  5. Петрова, Т.Г. Влияние длительного приема статинов на течение воспалительных заболеваний пародонта у больных ишемической болезнью сердца / Т.Г. Петрова и [и др.] // Пародонтология. – 2019. – № 1 (24). – С. 88–90.
  6. Шолкова, М.В. Плейотропные эффекты аторвастатина у пациентов с хронической обструктивной болезнью легких: влияние на показатели оксидативного стресса / М.В. Шолкова [и др.] // Проблемы здоровья и экологии. – 2019. – № 1 (59). – С. 20–24.
  7. Щинова, А.М. Снижение концентрации С-реактивного белка, измеренного высокочувствительным методом, на фоне высокоинтенсивной терапии статинами перед коронарным стентированием: возможная связь с последующим прогрессированием атеросклероза / А.М. Щинова [и др.] // Терапевт. архив. – 2019. – № 9 (91). – С. 10–15.
  8. Downs, J.R. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TехCAPS): additional perspectives on tolerability of long-term treatment with lovastatin / J.R. Downs [et al.] // Am. J. Cardiol. – 2001. – № 87 (9). – Р. 1074–1079.
  9. Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial // Lancet. – 2008. – № 372. – Р. 1231–1239.
  10. Guidelines ESC 2016 for the diagnosis and treatment of acute and chronic heart failure (Тhe task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) // Russ. J. Cardiol. – 2017. – № 1 (141). – Р. 7–81.
  11. Guidelines ESC/EAS 2019 for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk // Eur. Heart J. – 2020. – № 41 (1). – Р. 111–188.
  12. Kausik, K. Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes. Results From the PROVE -IT TIMI-22 Trial / К. Kausik [et al.] // JACC. – 2005. – Vol. 46, № 8. – Р. 1405–1410.
  13. Kjekshus, J. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics / J. Kjekshus [et al.] // Eur. J. Heart Fail. – 2005. – № 7 (6). – Р. 1059–1069.
  14. Lazzerini, P.E. Statins as a New Therapeutic Perspective in Myocarditis and Postmyocarditis Dilated Cardiomyopathy. / P.E. Lazzerini [et al.] // Cardiovasc. Drugs Ther. – 2013. – № 27. – Р. 365–369.
  15. Li, W.M. Immunoregulatory effects of atorvastatin on experimental autoimmune myocarditis in Lewis rats. / W.M. Li [et al.] // Immunol. Cell Biol. – 2006. – № 84 (3). – Р. 274–80.
  16. Nissen, S.E. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial / S.E. Nissen // Am. J. Cardiol. – 2005 – Sep 5; 96 (5A). – Р. 61–68.
  17. Smith, D.G. Cost of treating to a modified European Atherosclerosis Society LDL-C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin (Treat-to-Target Study) / D.G. Smith [et al.] // Clin. Drug Invest. – 1999. – № 17. – Р. 185–193.
  18. Takagi, H. Effects of statin therapy on abdominal aortic aneurysm growth: a meta-analysis and meta-regression of observational comparative studies / H. Takagi [et al.] // Eur. J. Vasc. Endovasc. Surg. – 2012. – № 44. – Р. 287–292.
  19. Tang, Q. Antiarrhythmic effect of atorvastatin on autoimmune myocarditis is mediated by improving myocardial repolarization. / Q. Tang [et al.] // Life Sci. – 2007. – № 80 (7). – Р. 601–608.
  20. Tousoulis, D. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. / D. Tousoulis [et al.] // Eur. Heart J. – 2016. – № 22. – P. 1723–1732.
  21. Van der Harst, P. Challenges for the Basis of Practice. Statins in the Treatment of Heart Failure / P. Van der Harst [et al.] // Circ. Heart Fail. – 2010. – № 3. – Р. 462–464.
  22. Wang, J. Q. Long-term clinical outcomes of statin use for chronic heart failure: a meta-analysis of 15 prospective studies / J.Q. Wang [et al.] // Heart Lung Circ. – 2014. – Vol. 23 (2). – P. 105–113.
  23. Watanabe, K. Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis. / K. Watanabe [et al.] // Inflamm. Allerg. Drug Targets. – 2011. – № 10 (3). – Р. 218–225.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. Correlation curve between the initial values of IgG to cardiomyosin and after treatment in patients with chronic myocarditis

Download (136KB)
Indexing metadata

Copyright (c) 2020 Ryzhman N.N., Grishaev S.L., Cherkashin D.V., Gladysheva E.V., Filippov V.Y., Kutelev G.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies